



EBRP accepts grant applications biannually and awards funding to competitive projects with the potential to lead to treatments and cures for EB. Each application is reviewed by our distinguished Scientific Advisory Board (SAB) of experts in the fields of genetics, dermatology, basic science, and biotechnology. In 2019, the SAB recommended funding for nine new research projects and six project renewals. In addition, we awarded funds for three ongoing research projects and for our EB Clinical Research Consortium, totaling over \$7.5M in awards. EBRP funded all efforts, securing matching funds from our partners EB Research Foundation of Australia, EB Medical Research Foundation and Cure EB.

2019 Newly Approved Research Projects

INSTITUTION	PROJECT NAME	PRINCIPAL INVESTIGATOR(S)	AMOUNT AWARDED
Columbia University	Development of a Drug Testing Platform for Recessive Dystrophic Epidermolysis Bullosa Squamous Cell Carcinoma Using Induced Pluripotent Cancer Cells	Joanna Jackow, PhD	\$551,250
Neem Biotech Limited	Identification of Ajoene Analogues for the Treatment of Epidermolysis Bullosa	Tracy Nevitt, PhD	\$112,400
University of Colorado	Developing an IPS Cell-Based Therapy for Epidermolysis Bullosa Simplex	Dennis R Roop, PhD Ganna Bilousova, PhD Igor Kogut, PhD Anna Bruckner, MD	\$518,638
Universite a Quebec a Chicoutimi	Inactivation of Epidermolysis Bullosa Simplex Dominant Mutations by Allele-Specific CRISPR/Cas9	Catherine Laprise, PhD Lucie Germain, PhD Jacques-P Tremblay, PhD	\$283,204
Centre for Human Genetics	Development of a Registry for Epidermolysis Bullosa in India	Ravi Hiremagalore, MD Gurudatta Baraka, PhD Arun Inamadar, MD Sacchidanand, MD	\$35,620
University College Dublin	Development of Gene-Editing Therapy to Restore Type VII Collagen for the Treatment of Recessive Dystrophic Epidermolysis Bullosa Using a Topical RNP CRISPR System	Wenxin Wang, PhD	\$117,053
Thomas Jefferson University	Epidermolysis Bullosa Community Cell Bank	Andrew South, PhD	\$151,651
Thomas Jefferson University	An Immune-Competent Mouse Model of Recessive Dystrophic Epidermolysis Bullosa Squamous Cell Carcinoma for Preclinical Therapeutic Testing	Andrew South, PhD	\$137,466
Stanford University	GMP Manufacturing of Autologous Esophageal Epithelial Cells for the Prevention of Esophageal Strictures	Anthony Oro, MD, PhD	\$300,421
TOTAL AWARDED			\$2,207,703

2019 Renewals and Ongoing Research Funding

INSTITUTION	PROJECT NAME	PRINCIPAL INVESTIGATOR(S)	AMOUNT AWARDED
Thomas Jefferson University	Targeting Fibrosis for Recessive Dystrophic Epidermolysis Bullosa Therapy in Preclinical Animal Models	Andrew South, PhD	\$159,054
University of Minnesota	Next Generation Genome Editing for Recessive Dystrophic Epidermolysis Bullosa	Jakub Tolar, MD, PhD	\$1,000,000
University of Southern California	Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations	Mei Chen, PhD David Woodley, MD	\$254,300
Stanford University	Topical and Intradermal Recombinant Type VII Collagen Protein Replacement Therapy for Recessive Dystrophic Epidermolysis Bullosa: A Placebo Controlled Phase 1 Clinical Trial	M. Peter Marinkovich, MD Jean Tang, MD, PhD David Olsen, PhD Gerhard Bauer, PhD	\$350,000
Stanford University	DISCOVER-JEB Study for Demystifying the Causes of Early Lethality in Generalized-Severe Junctional Epidermolysis Bullosa Due to Laminin-332 Mutations	M. Peter Marinkovich, MD Vamsi Krishna Yenamandra, MD, PhD Irina Gurevich, PhD Kerriann M Casey, DVM, DACVP	\$127,000
Stanford University	Computational Drug Repurposing for Epidermolysis Bullosa Simplex	Joyce Teng, MD, PhD Kavita Sarin, MD, PhD	\$187,782
Thomas Jefferson University	Targeting Fibrosis for Recessive Dystrophic Epidermolysis Bullosa Therapy in Preclinical Animal Models	Andrew South, PhD	\$159,054
FIBRX Derm	Development of Human Recombinant Decorin Core Protein as a Topical Anti-Scarring Therapy for Dystrophic Epidermolysis Bullosa	Professor Jean Tang, MD, PhD	\$1,250,000
Wings Therapeutics	Clinical Development of QR-313 for Treatment of Dystrophic Epidermolysis Bullosa	Mark De Souza, PhD	\$1,500,000
University of Minnesota	Bioprinting Workstation for Epidermolysis Bullosa Therapy Development	Jakub Tolar, MD, PhD	\$208,890
TOTAL AWARDED			\$5,196,080